Navigation Links
Dr. George Poste Named Non-Executive Vice Chairman of CDX Holdings, Parent of Caris Diagnostics and Caris Molecular Diagnostics

IRVING, Texas, Aug. 1 /PRNewswire/ -- CDX Holdings, a newly-formed holding company that is the parent company of Caris Diagnostics (Caris Dx) and Caris Molecular Diagnostics (CMDx), announced today that George Poste, D.V.M., Ph.D, F.R.C. Path, F.R.S., will be expanding his involvement with the company, serving as Non-Executive Vice Chairman and Chief Scientific Advisor of CDX Holdings and Non-Executive Chairman of CMDx. Dr. Poste has been a Director of Caris Dx, and now CDX Holdings, since November of 2006. He also acts as Senior Technical Advisor to Caris, Ltd., which owns a controlling stake in CDX Holdings.

Dr. Poste is Chief Scientist of the Complex Adaptive Systems Initiative and Director of The Biodesign Institute at Arizona State University. The research programs led by Dr. Poste combine research in biotechnology, nanotechnology, materials science and advanced computing. He also serves as Chief Executive of Health Technology Networks, a consulting firm that specializes in the application of genomic technologies and computing in healthcare. From 1992 to 1999, he was Chief Science and Technology Officer and president of Research & Development for SmithKline Beecham, where he oversaw the registration of 31 drug, vaccine and diagnostic products. Dr. Poste is a Fellow of the Royal College of Pathologists, a Fellow of the Royal Society and the UK Academy of Medicine, a Distinguished Fellow at the Hoover Institution of Stanford University and a member of the Council for Foreign Relations.

"George has been an invaluable asset to Caris since he first joined our Board in 2006. We look forward to getting the benefit of the additional contributions that George now will be able to offer in his more active role within our companies," said David D. Halbert, Chairman of CDX Holdings. "His understanding and foresight in diagnostics and personalized medicine is tremendous. He was instrumental in formulating our strategy that brought us into molecular diagnostics with our acquisition of Molecular Profiling, Inc., now called Caris MPI and the key subsidiary of CMDx, at the beginning of the year."

Dr. Poste has published over 350 scientific papers and co-edited 14 books on cancer, drug delivery and health policy. In 2004 he was named "R&D Scientist of the Year" by R&D Magazine and in 2006 he received the Einstein award from the Global Business Leadership Council. He previously served as chairman of the task force on bioterrorism for the U.S. Department of Defense. He serves as a member of the Defense Science Board of the Department of Defense and the Institute of Medicine Board of Global Health.

"I am honored to have the opportunity to work more closely with the distinguished team David has assembled at Caris Dx and Caris MPI," commented Dr. Poste. "I have appreciated the interactions I have experienced with the group in the past two years in forging the union of anatomic pathology and molecular diagnostics. I look forward to influencing and driving the companies' mission to accelerate the delivery of the highest quality personalized medicine into the marketplace to improve patient care and the efficient use of healthcare resources."

About CDX Holdings

CDX Holdings is the parent company of Caris Diagnostics and Caris Molecular Diagnostics, whose principal subsidiary is Caris MPI. Through its subsidiaries, CDX Holdings is a leading provider of the highest quality diagnostic, translational development and pharmaceutical services encompassing anatomic pathology and molecular testing. Formed in 1996, the company is headquartered in Irving, Texas, operates four laboratories: Irving, Texas; Phoenix, Arizona (2 sites); and Newton, Massachusetts, and provides services to well over 2,000 physicians nationally.

Caris Diagnostics provides world-class pathology services to physicians who treat patients in the community setting. The company provides academic-caliber medical consults through its industry-leading team of subspecialty fellowship and expert-trained pathologists in gastrointestinal and liver pathology, dermatopathology and hematopathology. Caris Diagnostics provides the highest levels of service to its customers and their patients through its state-of-the-art laboratories; proprietary, advanced clinical and technology solutions; and rigorous quality assurance programs.

Caris MPI provides advanced molecular analyses of patient samples through prognostic testing services and genomic and proteomic profiling to provide critical information to physicians treating cancer and other complex diseases. Furthermore, Caris MPI supports pharmaceutical companies and other researchers in their clinical trials for targeted therapeutics with custom genomic and proteomic analyses, analyte preservation, tissue procurement, and comprehensive reporting services. The company has strategic relationships with the International Genomics Consortium, US Oncology, the Translational Genomics Research Institute, and the Biodesign Institute of Arizona State University.

About Caris, Ltd.

Caris, Ltd. is a privately held investment partnership, with approximately $350 million of assets under management. Caris makes long-term, strategic investments principally in the private marketplace. Targeted sectors for Caris include health care, energy and financial services. Caris brings a successful track record of building sustainable business enterprises and partnering with management teams.

Additional information is available at and and

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board
2. George Butler Joins Bionovos Board of Directors
3. Koronis Pharmaceuticals Announces Appointment of Daniel H. Petree and George R. Painter, Ph.D. to Board of Directors
4. Seahorse Bioscience Receives Poster Award from the European Association for the Study of Obesity
5. AEterna Zentaris: Lead Investigator for Cetrorelix Trials in BPH Wins Best Poster Presentation Award at European Association of Urology Meeting in Milan
6. Rosetta Genomics to Present Multiple Posters at the Annual American Association of Cancer Research (AACR) Conference
7. DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
8. Fred Hutchinson Cancer Research Center and NSB POSTECH, Inc. to Collaborate on Development of New Class of Proteomic Microarrays
9. Derma Sciences Announces Clinical Poster on Use of MEDIHONEY(TM) Wound & Burn Dressings Wins First Place Award at APWCA
10. Bruker Announces Availability of New HUPO World Congress Proteomics Posters on Web Site
11. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
Post Your Comments:
(Date:11/26/2015)... MUMBAI , November 26, 2015 ... --> Accutest Research ... accredited Contract Research Organization (CRO), has ... Chase Cancer Center - Temple Health ... ,     (Photo: ) ...
(Date:11/25/2015)... Md. , Nov. 25, 2015  PharmAthene, Inc. ... Directors has adopted a stockholder rights plan (Rights Plan) ... net operating loss carryforwards (NOLs) under Section 382 of ... --> PharmAthene,s use of its NOLs ... "ownership change" as defined in Section 382 of the ...
(Date:11/25/2015)... LOS ANGELES and HOLLISTON, Mass. ... Regenerative Technology, Inc. (Nasdaq: HART ), a biotechnology ... announced that CEO Jim McGorry will present ... Tuesday, December 1, 2015 at 2:30 p.m. PT. The ... (link below) for 30 days. Management will also be ...
(Date:11/25/2015)... ... 25, 2015 , ... A long-standing partnership between the Academy ... been formalized with the signing of a Memorandum of Understanding. , AMA Executive ... Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, at AMA Headquarters ...
Breaking Biology Technology:
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
(Date:10/29/2015)... LA JOLLA, Calif. , Oct. 29, 2015 /PRNewswire-USNewswire/ ... released a new report titled, "DNA Synthesis and Biosecurity: ... how well the Department of Health and Human Services ... was issued in 2010. --> ... advances, but it also has the potential to pose ...
(Date:10/29/2015)... health pioneer, Joseph C. Kvedar , MD, describes ... wellness, and the business opportunities that arise from it ... Healthy Things . Long before health and wellness ... vice president, Connected Health, Partners HealthCare, was creating a ... the hospital or doctor,s office into the day-to-day lives ...
Breaking Biology News(10 mins):